Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-15
2006-08-15
Romeo, David S. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C514S012200, C530S300000
Reexamination Certificate
active
07091179
ABSTRACT:
Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.
REFERENCES:
patent: 4296100 (1981-10-01), Franco
patent: 4409237 (1983-10-01), Cairns et al.
patent: 5006343 (1991-04-01), Benson et al.
patent: 5254330 (1993-10-01), Ganderton et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 5915378 (1999-06-01), Lloyd et al.
patent: 5925012 (1999-07-01), Murphy-Chutorian et al.
patent: 6436902 (2002-08-01), Bäckström
patent: 6620784 (2003-09-01), Ferrara et al.
patent: WO 98/49300 (1998-11-01), None
patent: WO 00/40086 (2000-07-01), None
Sellke et al. (Jun. 1998) “Therapeutic Angiogenesis With Basic Fibroblast Growth Factor: Technique and Early Results.” Ann Throac Surg 65(6): 1540-1544.
Bikfalvi et al. (1997) “Biological Roles of Fibroblast Growth Factor-2.” Endocrine Reviews 18(1): 26-45.
Spallarossa et al. (Aug. 15, 1999) “Evaluation of Growth Hormone Administration in Patients With Chronic Heart Failure Secondary to Coronary Artery Disease.” The American Journal of Cardiology 84(4): 430-433.
NIH MeSH National Library of Medicine database (Jul. 27, 2004).
www.dictionary.com (Oct. 2004).
University of Newcastle upon Tyne's On-Line Medical Dictionary (Oct. 2004).
Vassenelli et al. (Dec. 1987) “Comparison of Different Pharmacological Interventions on Enzymatic Parameters During Acute Myocardial Infarction.” Clinical Biochemistry 20(6): 441-447.
Sato et al. (1997) “Hepatocyte growth factor (HGF): a new biochemical marker for acute myocardial infarction.” Heart Vessels 12(5): 241-6.
D'Souza et al. (Oct. 1978) “The significance of the MB isoenzyme in patients with acute cardiovascular disease with a normal or borderline total CPK activity.” Clinical Biochemistry 11(5): 204-209.
Buff Ernest D.
Ernest D. Buff & Associates LLC
Gamett Daniel C.
Pierson Theodore J.
Romeo David S.
LandOfFree
Methods of use of fibroblast growth factor, vascular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of use of fibroblast growth factor, vascular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of use of fibroblast growth factor, vascular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3636216